Open Access. Powered by Scholars. Published by Universities.®
Department of Medicine Faculty Papers
Thomas Jefferson University; Biomarkers; Cancer immunotherapy; Cost; Patient-reported outcomes; Summit; Value
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
The Value Of Cancer Immunotherapy Summit At The 2016 Society For Immunotherapy Of Cancer 31st Anniversary Annual Meeting, Howard L. Kaufman, Michael B. Atkins, Adam Dicker Md, Phd, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. Mcgivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu
The Value Of Cancer Immunotherapy Summit At The 2016 Society For Immunotherapy Of Cancer 31st Anniversary Annual Meeting, Howard L. Kaufman, Michael B. Atkins, Adam Dicker Md, Phd, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. Mcgivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu
Department of Medicine Faculty Papers
As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a clinically beneficial alternative to conventional therapies for a variety of malignancies. Characterized by broad clinical activity, durable response rates, distinct side effects, and unique response kinetics, immune-based agents are vastly different compared with traditional cytotoxic or targeted therapies. To date, however, value assessments in oncology have not focused on the unique aspects of cancer immunotherapy, which has resulted in a lack of understanding of the true value of …